Theragen Molecular Innovation Private Limited
About Theragen Molecular Innovation Private Limited
Data last updated:
Theragen Molecular Innovation Private Limited is a private limited company based in Chennai, Tamil Nadu, India. It operates in the biotechnology segment of the life sciences sector. It was incorporated on 15 December 2020 and has been in existence for over 6 years.
The company is registered with the Registrar of Companies (ROC), Chennai, under CIN U73100TN2020PTC140124. Its GSTIN is 33AAICT2944F1ZF (Tamil Nadu).
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Arumugam Sivaraman and Andal Arumugam.
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at No.153 1st Main Road Industrial Estate Perungudi, Chennai, Tamil Nadu, India – 600096.
As per the financials filed for FY 2025, the company reported a revenue of ₹40,000, a decline of 99% compared to the previous year. For the same year it recorded a net loss of ₹67,026 (net margin -167.6%) and EBITDA of -₹67,026 (EBITDA margin -167.6%). Revenue has declined at a compounded annual rate (CAGR) of 85% over three years.
The company has about 1 employee on its provident fund (EPFO) records.
Company details
Contact details
Theragen Molecular Innovation Private Limited's registered office is in Chennai, Tamil Nadu. Its e-mail address is in the company report.
- Email
- Registered AddressNo.153 1st Main Road Industrial Estate Perungudi, Chennai, Tamil Nadu, India – 600096
- IndustryLife Sciences, Biotechnology
To see the full contact details of Theragen Molecular Innovation Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Theragen Molecular Innovation Private Limited
FY 2025 filings availableTheragen Molecular Innovation Private Limited reported revenue of ₹40,000 (down 99% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has declined at a compounded annual rate (CAGR) of 85% over three years, including a 99% fall in the latest year. EBITDA fell 103% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹67,026 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹67,026 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -167.6% | ||||
| Net Profit Margin | -167.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Theragen Molecular Innovation Private Limited, buy the company report.
Board of directors of Theragen Molecular Innovation Private Limited
Theragen Molecular Innovation has 2 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Arumugam Sivaraman Also directs: R.K. Bio Technologies Private Limited, Keshava Gardens Private Limited, Arumugam Farms Private Limited and 5 more | Director | 15 Dec 2020 | 5 Years 10 Months | Current |
| Andal Arumugam Also directs: R.K. Bio Technologies Private Limited, Keshava Gardens Private Limited, Arumugam Farms Private Limited and 5 more | Director | 15 Dec 2020 | 5 Years 10 Months | Current |
Peer comparison
Theragen Molecular Innovation Private Limited is compared with the 4 companies closest to it by revenue in the Biotechnology industry (Biotechnology), with the same principal business activity (scientific research and development), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Genophe Biotech Private Limited | ₹44,240 (FY 2024) | -97.0% | Bangalore, Karnataka, India | |||
| Aeka Biochemicals Private Limited | ₹42,373 (FY 2024) | -92.0% | Thiruvananthapuram, Kerala, India | |||
| Mabtree Biologics India Private Limited | ₹41,511 (FY 2023) | -96.0% | Hyderabad, Telangana, India | |||
| Theragen Molecular Innovation Private Limitedthis company | ₹40,000 (FY 2025) | -₹67,026 | -167.6% | -99.0% | 1 | Chennai, Tamil Nadu, India |
| Sudarshan Biotech Private Limited | ₹34,000 (FY 2024) | Hyderabad, Telangana, India |
To see the full peer comparison of Theragen Molecular Innovation Private Limited, buy the company report.
Auditor
Theragen Molecular Innovation Private Limited is audited by K R SARANGAPANI & CO for the financial year 2021.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| K R SARANGAPANI & CO | FY 2021 | 050018S |
Shareholding
The shareholding of Theragen Molecular Innovation Private Limited is on record for FY 2021, split between promoters, domestic institutions, public shareholders and others.
| Shareholder category | FY 2021 |
|---|---|
| Promoters | |
| Domestic institutional investors (DII) | |
| Public | |
| Others |
To see the full shareholding pattern of Theragen Molecular Innovation Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Theragen Molecular Innovation Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Theragen Molecular Innovation Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Theragen Molecular Innovation Private Limited has a workforce of 1 employees on its EPFO records as of May 2023, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2023-24 | 1 |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 |
To see the full employee and EPFO history of Theragen Molecular Innovation Private Limited, buy the company report.
GST
Theragen Molecular Innovation has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 33AAICT2944F1ZF | Tamil Nadu | Active | 22 Feb 2021 |
To see the full GST registrations and return filing status of Theragen Molecular Innovation Private Limited, buy the company report.
Recent activity
Theragen Molecular Innovation Private Limited has 3 board changes on record since 2020: 2 appointments and 1 cessation. The latest: Chaniyilparampu Nanappan Ramchand ceased to be Director on 19 Feb 2025.
Frequently asked questions
Theragen Molecular Innovation is an active private limited company based in Chennai, Tamil Nadu, India. The company works in biotechnology, within the life sciences industry. It was incorporated on 15 December 2020 (6+ years old) and is registered under CIN U73100TN2020PTC140124.
Theragen Molecular Innovation has 2 current directors:
- Arumugam Sivaraman - Director
- Andal Arumugam - Director
The latest financial statements of Theragen Molecular Innovation on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 29 September 2025. Year-wise statements from FY 2021 are in the company report.
The GSTIN of Theragen Molecular Innovation is 33AAICT2944F1ZF, registered in Tamil Nadu.
The CIN (Corporate Identification Number) of Theragen Molecular Innovation is U73100TN2020PTC140124. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Theragen Molecular Innovation was incorporated on 15 December 2020, making it 6+ years old. It is registered with the Registrar of Companies, Chennai.
The peers of Theragen Molecular Innovation by revenue are Genophe Biotech Private Limited, Aeka Biochemicals Private Limited, Mabtree Biologics India Private Limited, Sudarshan Biotech Private Limited, all in the Biotechnology industry (Biotechnology), with the same principal business activity (scientific research and development).
Chaniyilparampu Nanappan Ramchand ceased to be Director on 19 Feb 2025. Andal Arumugam was appointed as Director on 15 Dec 2020. Arumugam Sivaraman was appointed as Director on 15 Dec 2020.
The registered office of Theragen Molecular Innovation is at No.153 1st Main Road Industrial Estate Perungudi, Chennai, Tamil Nadu, India – 600096.
Theragen Molecular Innovation operates in the life sciences industry, in the biotechnology segment.
Theragen Molecular Innovation can be reached at its registered office: No.153 1st Main Road Industrial Estate Perungudi, Chennai, Tamil Nadu, India – 600096.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
